Back to Newsroom

Apogenix – Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research

Heidelberg, Germany, Oct. 28, 2014 – Apogenix, a clinical stage biopharmaceutical
company, announced today that the final data of the completed phase II clinical trial with
APG101 in recurrent glioblastoma has been published in the peer-reviewed journal Clinical
Cancer Research.

The data demonstrates that treatment with APG101, a CD95 ligand-binding fusion protein,
in combination with radiotherapy is an innovative concept that has shown clinical
superiority in all study endpoints compared to treatment with radiotherapy alone. Both
progression-free survival at six months, the primary endpoint of the trial, and median
progression-free survival were met with statistical significance. In addition, an epigenetic
biomarker was identified that indicates response to treatment with APG101. The trial
showed a significant increase in median overall survival in biomarker-positive patients
treated with APG101, as previously reported.

Click here to read more